Description

1-(3-Chlorophenyl)-4-Hydroxymethyl-7,8-Dimethoxy-5H-2,3-Benzodiazepine is a high-purity, specialized benzodiazepine derivative with significant potential in pharmaceutical research and development. This compound serves as a critical advanced pharmaceutical intermediate or reference standard for the synthesis and analytical characterization of novel therapeutic agents. It is primarily required by pharmaceutical R&D laboratories, contract research organizations (CROs), and academic institutions engaged in neuroscience and medicinal chemistry programs.

Application

• Pharmaceutical Intermediate: A key building block in the synthesis of novel benzodiazepine-based active pharmaceutical ingredients (APIs) targeting neurological disorders.
• Reference Standard: Used for method development, validation, and quality control (QC) in analytical laboratories to ensure the purity and identity of related compounds.
• Medicinal Chemistry Research: Employed in structure-activity relationship (SAR) studies to explore modifications on the benzodiazepine core for enhanced efficacy and selectivity.
• Preclinical Studies: Serves as a candidate molecule or a metabolite analog in pharmacological and toxicological evaluations during early drug discovery.
• Chemical Library Synthesis: Used to create focused libraries of heterocyclic compounds for high-throughput screening against various biological targets.
• Academic Research: A valuable tool for universities and research institutes studying benzodiazepine pharmacology, receptor interactions, and synthetic methodologies.

Basic Information

Product Name	1-(3-Chlorophenyl)-4-Hydroxymethyl-7,8-Dimethoxy-5H-2,3-Benzodiazepine
CAS No.	142790-94-1
Molecular Formula	C18H17ClN2O3
Molecular Weight	344.79 g/mol
Synonyms	1-(3-Chlorophenyl)-4-(hydroxymethyl)-7,8-dimethoxy-5H-2,3-benzodiazepine; 7,8-Dimethoxy-1-(3-chlorophenyl)-4-(hydroxymethyl)-5H-2,3-benzodiazepine; 4-(Hydroxymethyl)-7,8-dimethoxy-1-(3-chlorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-5-one (tautomeric form); GYKI-52466 Hydroxymethyl Derivative; 2,3-Benzodiazepine Derivative; 1-(m-Chlorophenyl)-4-hydroxymethyl-7,8-dimethoxy-5H-2,3-benzodiazepine
EINECS	Contact for details

Quality Control

Our 1-(3-Chlorophenyl)-4-Hydroxymethyl-7,8-Dimethoxy-5H-2,3-Benzodiazepine is manufactured under a strict quality management system. Every batch undergoes comprehensive analytical testing, including HPLC, NMR, and MS, to ensure identity, purity, and consistency. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting the exact specifications and test results. We support cGMP and ISO compliant requirements for research and development applications.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). The compound is light-sensitive; prolonged exposure to light should be avoided to maintain stability.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.